Androgen induced oxidative stress inhibitors

A compound having the structure of Formula (I):

• wherein:
• R1, R3 and R4 are each independently selected from H, D, F, Cl, Br, I, —CN, —NO2, —OH, —CF3, —OCF3, —OR4, —NR6R6, C1-C6alkyl, C3-C8cycloalkyl, C1-C6heteroalkyl, C1-C6haloalkyl, C2-C8heterocycloalkyl, optionally substituted aryl, optionally substituted O-aryl, optionally substituted heteroaryl, —N═N-aryl, —NHS(═O)2R5, —S(═O)2N(R6)2, —N(R6)S(═O)2N(R6)2, —C(═O)CF3, —C(═O)NHS(═O)2R5, —S(═O)2NHC(═O)R5, —N(R6)2, —N(R6)C(═O)R6, —N(R6)C(═O)N(R6)2, —N(R6)C(═O)OR5, —CO2R6, —C(═O)R6, —OC(═O)R5, —OC(═O)N(R6)2, —CON(R6)2, —SR6, —S(═O)R5, and —S(═O)2R5;
• each R5 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, aryl, and benzyl;
• each R6 is independently selected from H, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, aryl, and benzyl;
• R2 is selected from H, OH, OC(═O)C1-C6alkyl, or OC(═O)H;
• n is an integer selected from 0-4;
• m and o are each independently an integer selected from 0-5;
• or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof.